In recent months, multiple investigations by federal agencies, Congressional committees, states and media outlets have exposed ways pharmacy benefit managers (PBMs) and insurers profit off medicines at the expense of patients.
Just last week, the Federal Trade Commission (FTC) announced it’s suing the big PBMs for “artificially inflating” medicine prices and “boosting PBM profits at the expense of vulnerable patients.”
So why then would Senator Bernie Sanders (I-VT) hold a hearing on drug prices without including PBMs and insurers? Instead of holding these middlemen accountable, he’s giving them a free pass to continue driving up costs and denying coverage of medicines while they rake in record profits.
Here are five important facts that are missing from Sen. Sanders’ political narrative.
1. PBMs and insurers decide what medicines people can get and what they pay at the pharmacy, not the manufacturers. These middlemen get billions of dollars in rebates that lower what they pay for medicines, but often don’t use those savings to lower patients’ costs at the pharmacy. In fact, a recent study from the Bureau of Economic Analysis found that between 2016 and 2020, patient out-of-pocket costs grew faster than net prices faced by insurers.
2. Competition in the market is already dramatically lowering net prices for new, innovative diabetes and obesity medicines and will continue to do so. Rebates and discounts for prominent anti-obesity medicines can lower the net prices for these medicines by up to 79%. New estimates show there could be 16 new medicines to treat obesity competing in the market in the next five years, which will likely further drive down costs.
3. Medicines that treat and prevent obesity are dramatically improving the health of patients and can help deliver hundreds of billions in savings for the system and taxpayers. The obesity and overweight epidemic results in an estimated $1.72 trillion in medical costs and loss of productivity annually. If insurers covered obesity medicines, Medicare would save up to $245 billion over 10 years. Every time new groundbreaking medicines are approved critics claim they will bankrupt the health care system. We heard similar attacks when breakthrough cholesterol and Hepatitis C treatments came to market. But those claims never pan out. Competition lowers costs and innovative medicines drive savings across the system.
4. The cost to copy a medicine doesn’t reflect the costs of researching and developing a new one and doesn’t cover failure costs. Bringing a new medicine to market takes $2.6 billion and 10-15 years and just 12% of drugs entering clinical trials are successful in reaching FDA approval. Removing the incentive for innovation would result in fewer new medicines for patients.
5. Deceptive price comparisons could damage innovation and patient access in the U.S. The U.S. leads the world in biopharmaceutical innovation which allows Americans better and quicker access to life-changing cures and treatments, in some cases years ahead of other countries. Even with our innovative advancements, the U.S. spends about the same share of health care spending, 14%, as other countries.
Remember — repeating a false claim doesn’t make it true. If Sen. Sanders and others want to lower out-of-pocket costs for patients, they should take on PBMs and insurers for denying patients coverage to life-changing medicines and driving up what they pay at the pharmacy.
Nick McGee
Nick McGee is deputy vice president, public affairs, at PhRMA focusing on communications strategies and activities for the organization’s advocacy priorities.
Nick McGee
What AARP isn’t telling seniors about MFN
Policymakers should improve patient access and reject price controls
Insurers blame GLP-1s for rising costs. The data tells a different story.
The FTC’s PBM enforcement actions gave us a glimpse behind the curtain; it’s time to let the light in.
Nearly 1 in 4 patients initially denied access to IRA medicines
Message to USAging: Providers are raising concerns about coverage barriers
New PBM principles don't change the fundamental challenge: Access to lower-cost medicines
340B’s reality: A booming business for hospitals, pharmacies and corporate giants
Insurers are blaming medicines for premium hikes in Massachusetts. The state's own data suggests otherwise.
Briefing: Capitol Hill panel on "Healthcare Denial Crisis in America"
Survey confirms too many insured Americans face barriers to reliable health care
70% DENIED: How insurance denials are delaying and preventing care for millions of Americans
Hospitals drive nearly 80% of the U.S. health spending gap
Insurers routinely block seniors’ access to medicines in Medicare Part D
No hassle, hidden markups or fees: AmericasMedicines.com
The Federal Trade Commission (FTC) takes important action to highlight and curb PBM abuses
Separating fact from fiction in the medicine supply chain
50-state poll says Americans are concerned that hospital markups hurt patients
Three things you should know from the insurer CEO congressional hearings
Can’t get your medicine? Don’t count on your insurer.
Stop, collaborate and re-evaluate: ICER’s pricing report
California’s landmark PBM crackdown: A wake-up call for reform
Middlemen mark up drug prices and keep discounts meant for you
Putting patients first: Breaking down barriers to care
Direct purchase programs can lower costs for patients
PBMs say they want lower priced medicines, so why don’t they cover them?
Historic biopharmaceutical investments: A prescription for America’s future
Why states struggle to deliver savings: Middlemen and 340B siphon dollars from patients and states
PBMs are hiding hurdles to essential care
New study: PBMs and commercial insurers are quietly blocking prescription access
North Carolina puts patients first with rebate pass-through law
PBMs, not patents, are blocking access to lower-cost medicines
Medicare Part D plans initially denied medicines for more than 70% of patients in four chronic disease areas
New “Balance the Scales” campaign highlights why Americans pay more for prescription medicines
How the 340B hospital markup program and PBMs drive up costs for U.S. patients
Foreign first pricing schemes don’t address why Americans pay more
The AHIP premium dollar corrected (again)
PBMs launch new ad campaign to block reforms
When middlemen own it all, patients pay the price
3 myths critics get wrong about intellectual property
New report finds more abuse of 340B program by hospitals and drug middlemen
A closer look at how health care consolidation drives up patient costs, creates barriers to care
Health care practitioners sound the alarm on middlemen-imposed barriers to patient care, need for policy change
Congress Keeps PBMs in the Hot Seat
Wrapping up the J.P. Morgan Healthcare Conference
FTC finds PBMs make billions in profit from marking up cancer, other critical generic drugs
PhRMA CEOs Tee Up Next Week's Health Care Conference
New study: Entities that don’t make medicines get half of what is spent on those medicines
Three things to know about 340B contract pharmacies
The PBM industry's desperate attempt to stop reform
PhRMA launches new ad calling for Congress to make sure savings go to patients, not PBMs
ICYMI: Grounding policy reforms in real lived patient experiences is key to improving outcomes
New PES survey: Out-of-pocket costs lead key health care priorities ahead of the November election
Guest Post: My health care vote
Insurers continue shifting more costs on to patients
Americans speak out on health insurance barriers and need for policy change, according to the latest Patient Experience Survey
ICYMI: The powerful companies driving local drugstores out of business
Hispanic Heritage Month: Fighting for Hispanic patients
Key voter insights two months from Election Day
Patient priorities in the 2024 election
Voters across all 50 states want state policymakers to focus on health insurance and PBM practices
WTAS: Voters voice concerns about PBM abuses, call on policymakers to act
PhRMA launches new ad in campaign exposing ways middlemen drive up costs
FTC report confirms PBMs profit at the expense of patients
New 50-state poll Americans want to hold health insurers and PBMs accountable for high out-of-pocket costs and other practices
ICYMI: Hidden markups at mail-order pharmacies increase costs for employers
ICYMI: What patients care about this election year
ICYMI: The Opaque Industry Secretly Inflating Prices for Prescription Drugs
ICYMI: Health care policy should be driven by patients, not politics
PhRMA Warns Federal Agencies: Consolidation and vertical integration among insurers, PBMs, and hospitals threaten patients
ICYMI: Innovation transforms lives but misguided federal policies threaten patient outcomes
Ongoing federal probes shed light on PBM and insurer practices
Critics repeat same, misleading narrative on potential “costs” of new medicines
WTAS: The consequences of consolidation and vertical integration
IRA is already negatively impacting access to medicines in Part D
Insurance data: PBM reform has no material impact on premiums
New study finds insurers and PBMs increasing access restrictions in Medicare Part D
3 Takeaways from POLITICO’s Health Care Summit
PBMs using 340B program to drive profits at patients’ expense
Four years later, Maryland board still hasn’t delivered for patients
How the 340B program became a PBM giveaway
ICYMI: When middlemen get in the way, it’s the patients who lose
Get the facts on PCMA’s newest attempt to avoid accountability
Increased use of prior authorization in Medicaid is blocking access for patients
ICYMI: WSJ — Same Drug, Two Prices: Why the Higher Price Prevails
ICYMI: 3 takeaways on the IRA’s unintended consequences from America’s Physician Groups’ 2023 annual fall conference
One year to Election Day: Four voter priorities to watch
ICYMI: Scott LaGanga and Matt Salo deliver a State of the Industry Report
New poll shows strong bipartisan support for PBM reform
4 truths about state government price setting
ICYMI: Government watchdog report finds patients in Medicare Part D paid billions more for medicines than insurers and PBMs
New analysis shows PBMs use fees as a profit center
It’s PBMs, not patents, blocking competition
New PhRMA ad exposes yet another way PBMs get between patients and their medicines
Navigating the Patient Experience Survey: Protecting Lifelines to Access and Innovation
Three things to know from the latest Patient Experience Survey
ICYMI: PBM exec admits choosing profits over patients
Insulin: Key Facts on Access & Affordability
4 key facts on medicine prices and spending
4 Things to know about PhRMA’s new 50-state poll
New PhRMA ad campaign sheds light on PBM abuses
Three facts about health care spending
AHIP’s latest misinformation campaign & what it’s trying to hide
ICYMI: PhRMA President and CEO Stephen J. Ubl discusses patient affordability
States can support access to medicine as COVID-19 Public Health Emergency ends
Arkansas puts patients first with new share the savings law
Key Trends: Patient experience data reveal how insurers and middlemen impose barriers in health care
Insurer and PBM tactics are shifting higher costs to patients with chronic and complex conditions
Holding pharmacy benefit managers accountable
Stopping pharmacy benefit managers from “gaming the system”
Senate hearing to examine bipartisan reforms to rein in middlemen
Minnesota lawmakers are letting PBMs off the hook, and threatening patients’ access to medicines
ICYMI: PhRMA COO Lori Reilly speaks about the health care agenda for the next Congress
In their own words: Financial barriers exacerbate access challenges for insured Americans
Medicare Part D open enrollment and what recent changes mean for beneficiaries
New data show how insurers and middlemen shift Rx costs onto patients
In their own words: Insured Americans struggle to navigate complex coverage
Many seniors are paying more for Part D medicines than their insurer
New comments outline ways to protect patients from health plans and PBMs who profit from patient assistance
Busting 3 Myths About Copay Coupons
Mental Illness Awareness Week – A time for reflection
Navigating the patient experience: Burdens and barriers standing between patients and their care
Making coupons count for patients at the pharmacy counter
Insulin and reconciliation
Making coupons count for patients with HIV
Patients win as West Virginia implements first-in-nation share the savings policy
3 things voters are concerned about when it comes to their health care coverage
Copay assistance is a lifeline for patients. So why are insurers blocking it?
Patients support state action requiring PBMs and insurers to share savings and cap costs for medicines
New poll shows voters sounding the alarm on health insurance companies and PBMs
PhRMA warns of the growing influence of middlemen over patient access and out-of-pocket costs for patients
Report finds PBMs are increasingly restricting patient access to medicines
ICYMI: PhRMA COO Lori Reilly spotlights efforts to improve health care in 2022 and beyond
Study finds insurance barriers disproportionately burden patients with chronic illness
5 public opinion polling trends to watch
Analysis: States can help patients save nearly $1,000 annually on their medicines
How standardized plans can improve patients’ access to medicines
The patient experience: Uncovering the barriers to care for insured Americans
Veterans Affairs 101: Three charts show how the VA system differs from Medicare
If drug prices are growing below the rate of inflation, why are patients still feeling the sting at the pharmacy?
The patient experience: Insurance barriers continue to impede access to health care, especially among the country’s underserved
PhRMA submits comments urging CMS to withdraw coverage proposal
Government price setting won’t stop insurers from shifting costs to patients
New comments outline ways to counteract cost-shifting insurance trends
Patients need to pay less for their medicines. States can help.
CBO reaffirms our innovation ecosystem leads to improved lives, long-term savings
The patient experience: Insurance design hurdles lead to access issues for too many Americans
To drive up profits, hospitals continue unnecessary medicine mark-ups, burdening patients, employers and health care system
New insulin report highlights how incentives benefit middlemen, harm patients
Key facts: The final rebate rule will be a positive change for patients
Election insights: Voter priorities in the states
PhRMA submits comments on ways to refocus the 340B program on America’s vulnerable patients
Study finds middlemen excluded nearly 850 medicines from formularies this year
PhRMA comments on HHS proposed rule on manufacturer cost-sharing assistance and accumulator adjustment programs
340B Spotlight: How for-profit middlemen are taking advantage of a program meant to support nonprofit entities and patients
Five key facts about the market for insulins
The PBM story you haven’t heard: Hidden fees quadrupled in two years
OptumRX: Sharing rebates with patients is “worth it”
New whitepaper identifies reasons why ICER’s cost-effectiveness analyses are not useful for payers
Event tomorrow: Making the biopharmaceutical supply chain work for patients
Advance price notification: A transparency measure that fails patients
New Let’s Talk About Cost ads highlight how copay accumulator programs could leave patients financially exposed
ICYMI: Two PBM reports show dramatic slowdown in medicine spending growth
Copay coupons can help ease patients’ out-of-pocket costs
ICYMI: New report outlines steps for greater transparency in health care
Why won’t the insurance industry tell the truth about medicine costs?
PBMs and insurers off the hook: Sen. Sanders’ selective hearing on drug costs
Health Insurance
PBMs/Insurance
PBMs and insurers off the hook: Sen. Sanders’ selective hearing on drug costs
PBMs and insurers off the hook: Sen. Sanders’ selective hearing on drug costs